SEC Tracker
Get the app

Dyadic International DYAI

Dyadic International Q1 FY24: revenue $335K

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Dyadic International reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$335KNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$2.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Cash and cash equivalents$10.6MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  4. Cash from operations−$1.1MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Dyadic International files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Curis CRIS public float $25M, Jun 30, 2025
  2. Passage BIO PASG public float $25M, Jun 30, 2025
  3. Aptose Biosciences APTOF public float $22M, Jun 28, 2025
  4. Outlook Therapeutics OTLK public float $27M, Mar 31, 2025, over 18 months old
  5. Armata Pharmaceuticals ARMP public float $21M, Jun 30, 2025